Vertex pharmaceuticals incorporated VRTX.US Overview
VRTX AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
VRTX Current Performance
-1.73%
Vertex pharmaceuticals incorporated
-1.83%
Avg of Sector
-0.40%
S&P500
VRTX Key Information
VRTX Revenue by Segments
Browsing restrictions can be lifted for a fee.
VRTX Net Income
Browsing restrictions can be lifted for a fee.
VRTX Cash Flow
Browsing restrictions can be lifted for a fee.
VRTX Profit Margin
Browsing restrictions can be lifted for a fee.
VRTX PE Ratio River
Browsing restrictions can be lifted for a fee.
VRTX Financial Forecast
Browsing restrictions can be lifted for a fee.
VRTX Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
VRTX Profile
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Price of VRTX
VRTX FAQ
When is VRTX's latest earnings report released?
The most recent financial report for Vertex pharmaceuticals incorporated (VRTX) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating VRTX's short-term business performance and financial health. For the latest updates on VRTX's earnings releases, visit this page regularly.
What is the operating profit of VRTX?
According to the latest financial report, Vertex pharmaceuticals incorporated (VRTX) reported an Operating Profit of 632.3M with an Operating Margin of 22.83% this period, representing a decline of 44.51% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is VRTX's revenue growth?
In the latest financial report, Vertex pharmaceuticals incorporated (VRTX) announced revenue of 2.77B, with a Year-Over-Year growth rate of 2.96%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much cash does VRTX have?
At the end of the period, Vertex pharmaceuticals incorporated (VRTX) held Total Cash and Cash Equivalents of 4.67B, accounting for 0.2 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does VRTX go with three margins increasing?
In the latest report, Vertex pharmaceuticals incorporated (VRTX) achieved the “three margins increasing” benchmark, with a gross margin of 86.9%%, operating margin of 22.83%%, and net margin of 23.3%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess VRTX's profit trajectory and future growth potential.
Is VRTX's EPS continuing to grow?
According to the past four quarterly reports, Vertex pharmaceuticals incorporated (VRTX)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 2.52. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of VRTX?
Vertex pharmaceuticals incorporated (VRTX)'s Free Cash Flow (FCF) for the period is 778.2M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 37.15% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of VRTX?
The latest valuation data shows Vertex pharmaceuticals incorporated (VRTX) has a Price-To-Earnings (PE) ratio of -116.86 and a Price/Earnings-To-Growth (PEG) ratio of -1.66. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.